Diabetes Care for Your Patients | Tandem Diabetes Care

In real-world studies, Tandem Diabetes Care automated insulin delivery demonstrated:

Immediate Improvements

Overall time in range increase of 10% resulting in 2.4 more hours per day spent in range compared to prior therapy and sustained over 12 months.¹

Decrease in Burden

Users experienced a 42% reduction in diabetes impact and meaningful improvements in quality of life including trust in the system and greater BG control.²

More Control Overnight

Users experienced more than 90% time in range between the hours of 4 am to 7 am while using Control‑IQ technology with a Tandem insulin pump.¹

Note: Studies were conducted using the t:slim X2 insulin pump with Control-IQ technology and Dexcom G6 CGM^† sensor.

Patients can choose the Tandem pump that best fits their lifestyle

Impressively Small

Tandem Mobi System

This insulin pump can be worn almost anywhere, giving you more options for how you manage your diabetes. It’s powered by Control-IQ technology and is controllable by a personal, compatible iPhone.^‡

Explore Features

Color Touchscreen

t:slim X2 Insulin Pump

Sleek and modern, the t:slim X2 pump is easy to use with a color touchscreen and can pair with multiple CGM sensors. When used with Control‑IQ technology, it is the #1 rated automated insulin delivery system.³

Explore Features

Control-IQ Technology:
The Great Equalizer

Control-IQ technology helps users achieve improvements in time in range irrespective of starting A1c or prior insulin regimen.⁴

See the Evidence

Time In Range Improvements By Baseline Alc Graph

Tandem SourceReporting Made Simple

Tandem Source is a platform for healthcare providers to see important diabetes therapy data, access patient reports, and find the tools to help patients manage their diabetes.

Explore Reports

Provider Resources

Browse educational resources and product tips so your patients can make the most of their experience.

View Resources

Clinical Evidence

Clinical studies have demonstrated the safety, efficacy, and ease of use of Tandem automated insulin delivery.

See Studies

Industry Events

Browse live conferences, virtual events, and learning environments attended or hosted by Tandem.

Browse Events

Stay Connected

Sign up for our monthly newsletter and stay up to date on pump software updates, outcomes, and important patient information.

Responsible Use of Control‑IQ Technology

Even with advanced systems such as Control-IQ technology, users are still responsible for actively managing their diabetes. Control-IQ technology does not prevent all high and low blood glucose events. The system is designed to help reduce glucose variability, but it requires that users accurately input information, such as meals and periods of sleep or exercise. Control-IQ technology will not function as intended unless all system components, including CGM, infusion sets and pump cartridges, are used as instructed. Importantly, the system cannot adjust insulin dosing if the pump is not receiving CGM readings. Because there are situations and emergencies that the system may not be capable of identifying or addressing, users should always pay attention to their symptoms and treat accordingly.

* If glucose values are predicted to be above 180 mg/dL, Control-IQ technology calculates a correction bolus using the Personal Profile settings and a target of 110 mg/dL and delivers 60% of that value.

† CGM sold separately.

‡ Our mobile apps require a compatible smartphone model and operating system (sold separately). Only available to pump users who reside in the USA.

References

1. Breton MD, Kovatchev BP. One year real-world use of the Control-IQ advanced hybrid closed-loop technology. Diabetes Technol Ther. 2021;23(9):601-608. doi: 10.1089/dia.2021.0097.

2. Graham R, Mueller L, Manning M, et. al. Real-World Use of Control-IQ Technology is Associated with a Lower Rate of Severe Hypoglycemia and Diabetic Ketoacidosis than Historical Data: Results of the Control-IQ Observational (CLIO) Prospective Study. Diabetes Technol Ther. 2024;26(1):24-32. doi: 10.1089/dia.2023.0341.

3. dQ&A US Patient Panel Q3 2023 (July-Sept. 2023)

4. Beck RW, Kanapka LG, Breton MD, et al. A Meta-Analysis of Randomized Trial Outcomes for the t:slim X2 Insulin Pump with Control-IQ technology in Youth and Adults from Age 2 to 72. Diabetes Technol Ther. 2023;25(5):329-342. doi: 10.1089/dia.2022.0558.

Important Safety Information

RX ONLY.

Indications for Use

Tandem Mobi system: The Tandem Mobi insulin pump with interoperable technology (the pump) is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is intended for single patient, home use and requires a prescription. The pump is indicated for use in individuals 6 years of age and greater.

t:slim X2 insulin pump: The t:slim X2 insulin pump with interoperable technology is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is intended for single patient use. The pump is indicated for use with NovoLog or Humalog U-100 insulin. The pump is indicated for use in individuals 6 years of age and greater.

Control-IQ technology: Control-IQ technology is intended for use with compatible integrated continuous glucose monitors (iCGM, sold separately) and alternate controller enabled (ACE) pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ technology is intended for the management of Type 1 diabetes mellitus in persons 6 years of age and greater. Control-IQ technology is intended for single patient use. Control-IQ technology is indicated for use with NovoLog or Humalog U-100 insulin.

Warning: Control-IQ technology should not be used by anyone under the age of 6 years old. It should also not be used in patients who require less than 10 units of insulin per day or who weigh less than 55 pounds.

Control-IQ technology is not indicated for use in pregnant women, people on dialysis, or critically ill patients. Do not use Control-IQ technology if using hydroxyurea. Users of a Tandem insulin pump and Control-IQ technology must use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts, alarms, and reminders. The Tandem pump must be removed before MRI, CT, or diathermy treatment. Visit tandemdiabetes.com/safetyinfo for additional important safety information.

The Tandem Source platform is intended for use by individuals with diabetes mellitus who use Tandem Diabetes Care insulin pumps, their caregivers, and their healthcare providers in home and clinical settings. The Tandem Source platform supports diabetes management through the display and analysis of information uploaded from Tandem insulin pumps.

Tandem Diabetes Care #1 in Overall Satisfaction

According to U.S. healthcare providers

Immediate Improvements

Decrease in Burden

More Control Overnight

Patients can choose the Tandem pump that best fits their lifestyle

Impressively Small

Color Touchscreen

Control-IQ Technology:
The Great Equalizer

Tandem SourceReporting Made Simple

Provider Resources

Clinical Evidence

Industry Events

Stay Connected

Software

Information

Disclosures

Tandem Diabetes Care #1 in Overall Satisfaction

According to U.S. healthcare providers

Immediate Improvements

Decrease in Burden

More Control Overnight

Patients can choose the Tandem pump that best fits their lifestyle

Impressively Small

Color Touchscreen

Control-IQ Technology: The Great Equalizer

Tandem SourceReporting Made Simple

Provider Resources

Clinical Evidence

Industry Events

Stay Connected

Control-IQ Technology:
The Great Equalizer